FDA approves Pfizer's rheumatoid arthritis treatment

Share this article:
FDA approves Pfizer's rheumatoid arthritis treatment
FDA approves Pfizer's rheumatoid arthritis treatment
Federal regulators recently approved Pfizer's new Xeljanz treatment for rheumatoid arthritis. Xeljanz was approved for patients with moderate to severe rheumatoid arthritis who did not benefit from the oral treatment methotrexate. Xeljanz can be used with methotrexate and certain other treatments. Industry analysts have predicted the new drug, also known as tofacitinib, could grow to sales of $3 billion annually. Xeljanz is taken in 5-milligram pills twice daily.  About 1.3 million people in the United States suffer from rheumatoid arthritis, which can cause problems in wound healing.
Share this article:

More in Products

LeadingAge's CAST releases EHR matrix selection tool

LeadingAge's Center for Aging Services Technologies released its 2014 version of a tool to let long-term providers choose the best electronic health record for their facility.

New magnetic badges debut

New magnetic badges debut

Imprint Plus has introduced The Mighty Badge name badge kit, which allows users to create reusable but personalized badges.

Hollister Incorporated celebrates antibacterial foam dressing

Hollister Incorporated celebrates antibacterial foam dressing ...

Hollister Incorporated's new Hydrofera Blue Ready antibacterial foam dressing has been named a "Top 10 Innovation in Podiatry" according to the Podiatry Today journal, as well as a "Top Innovation ...